CureVac N.V.

NASDAQ:CVAC  
14.21
+0.60 (+4.41%)
Mergers / Acquisitions

Curevac NV Says Total Consideration for Acquisition of Frame Therapeutics is Valued at EUR 32 Million

Published: 06/08/2022 20:22 GMT
CureVac N.V. (CVAC) - Dgap-news: Curevac Accelerates Oncology Strategy With Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform.
Total Consideration for Acquisition of Frame Therapeutics is Valued at EUR 32 Million.
Consideration Will Be Paid in Curevac Shares.